Standard BioTools Purchases Carterra LSA-XT System to Enhance SomaScan Platform
Standard BioTools Inc., a biotechnology company, has recently acquired the LSA-XT system from Carterra, a leading provider of screening and characterization solutions for molecules. The purpose of this purchase is to further validate Standard BioTools’ SomaScan platform by measuring the kinetic properties of SOMAmer Reagents, providing more accurate information about protein binding and biomarker characterization to its customers.
By incorporating the LSA-XT system into its operations, Standard BioTools aims to accelerate data delivery and enhance the validation process for the SomaScan platform. SOMAmer Reagents are short modified nucleic acids that have the ability to bind with high affinity and specificity to target proteins. These reagents play a crucial role in the identification and measurement of various biomarkers, offering valuable insights into disease detection and treatment.
The LSA-XT system, developed by Carterra, is renowned for its high-throughput capabilities in screening and characterizing large and small molecules. With this state-of-the-art instrument, Standard BioTools will gain the ability to precisely measure the kinetic properties of SOMAmer Reagents, enabling greater accuracy in protein-protein interaction studies. This will provide comprehensive and reliable information about protein binding and biomarker characterization, thereby enhancing the utility of the SomaScan platform.
The acquisition of the LSA-XT system showcases Standard BioTools’ commitment to staying at the forefront of advanced technologies in the biotechnology sector. By investing in this cutting-edge instrument, the company is poised to provide its customers with more robust and reliable data that can drive better decision-making in biomedical research and drug development.
With the integration of the LSA-XT system into its operations, Standard BioTools aims to further solidify its position as a leader in the field of biotechnology. By offering a comprehensive and highly accurate platform for protein analysis, the company is well-positioned to cater to the evolving needs of its customers and contribute significantly to advancements in the healthcare industry.
Overall, the purchase of the Carterra LSA-XT system by Standard BioTools signifies a significant step forward in enhancing the SomaScan platform’s capabilities. By harnessing the power of the LSA-XT system, Standard BioTools is poised to deliver precise information about protein binding and biomarker characterization, enabling greater validation and accelerating data delivery to its customers.
Comments